BridgeBio Pharma Inc’s recently made public that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $1.71 million on Jul 02 ’25. In the deal valued at $42.73 per share,40,000 shares were sold. As a result of this transaction, Kumar Neil now holds 955,686 shares worth roughly $44.41 million.
Then, Kumar Neil sold 40,000 shares, generating $1,701,400 in total proceeds. Upon selling the shares at $42.54, the Chief Executive Officer now owns 975,686 shares.
Before that, VIKING GLOBAL INVESTORS LP sold 3,500,000 shares. BridgeBio Pharma Inc shares valued at $154,000,000 were divested by the 10% Owner at a price of $44.00 per share. As a result of the transaction, VIKING GLOBAL INVESTORS LP now holds 18,555,375 shares, worth roughly $862.27 million.
Oppenheimer upgraded its BridgeBio Pharma Inc [BBIO] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Redburn Atlantic began covering BBIO with “Buy” recommendation on March 31, 2025. Scotiabank started covering the stock on October 16, 2024. It rated BBIO as “a Sector outperform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 0.43% to $46.47. Over the last five days, the stock has gained 5.64%. BridgeBio Pharma Inc shares have risen nearly 80.82% since the year began. Nevertheless, the stocks have risen 69.35% over the past one year. While a 52-week high of $46.80 was reached on 07/10/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 45.88, which if violated will result in even more drops to 45.29. On the upside, there is a resistance level at 46.91. A further resistance level may holdings at 47.35.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-06-13, dropping by -1.28 million shares to a total of 21.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 22.4 million shares. There was a decline of -6.05%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 03, 2024 when Oppenheimer began covering the stock and recommended ‘”a Perform”‘ rating .
